The evolving need for patient reported outcome data in determining choice of immune therapy treatment

Jennifer Saultz; Richard T Maziarz

doi:10.1016/j.medj.2021.07.002

The evolving need for patient reported outcome data in determining choice of immune therapy treatment

Med. 2021 Aug 13;2(8):907-911. doi: 10.1016/j.medj.2021.07.002.

Authors

Jennifer Saultz¹, Richard T Maziarz²

Affiliations

¹ Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.
² Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA. Electronic address: maziarzr@ohsu.edu.

PMID: 35590167
DOI: 10.1016/j.medj.2021.07.002

Abstract

Cellular therapy has changed the cancer treatment landscape and potential associated toxicities. The traditional short-term toxicities of chemotherapy-induced nausea, vomiting, and diarrhea are replaced by complex immune activation syndromes and immunologic organ-specific toxicities. Understanding the long-term consequences and impact of these therapies on patient quality of life is necessary.

MeSH terms

Antineoplastic Agents* / adverse effects
Humans
Nausea / chemically induced
Patient Reported Outcome Measures
Quality of Life*
Vomiting / chemically induced

Substances

Antineoplastic Agents